Published July 21, 2022 | Version v1
Journal article Open

Extended data for 'Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial'

Authors/Creators

  • 1. Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne and Wear
  • 2. Translational and Clinical Research Institute, NU Cancer, Newcastle upon Tyne, Tyne and Wear
  • 3. Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, Tyne and Wear
  • 4. Population Health Sciences, Newcastle University, Newcastle upon Tyne, Tyne and Wear
  • 5. Velindre University NHS Trust, Cardiff, CF15 7QZ
  • 6. Trial Management Group, VARIANT Trial, Newcastle-Upon-Tyne, NE1 7RU
  • 7. University Hospitals Bristol NHS Foundation Trust, Bristol
  • 8. University of Southampton, Southampton, Hampshire
  • 9. Queen's University Belfast, Belfast
  • 10. Institute of Cancer Sciences, University of Glasgow, Glasgow
  • 11. Velindre University NHS Trust, Cardiff

Description

Extended data for ‘Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial’

Files

Files (384.5 kB)

Name Size Download all
md5:ed8439cec234a50a15931610c97b5d85
209.9 kB Download
md5:c8f4c8192c5bbebba8d6d5532faeda58
174.6 kB Download